Chongqing Precision Biotech Co., Ltd

This early-stage study tests a new treatment called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, and ovarian cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have a specific marke…

This early-phase study tests a new drug called PIC1 injection in 18 adults with B-cell Non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and side effects, while also seeing if the drug can shrink tumors. Participants must be b…

This early-stage study is testing a new treatment using specially engineered immune cells (CAR-T cells) in 11 children with severe rheumatic diseases like juvenile dermatomyositis, arthritis, and scleroderma that haven't responded to standard therapies. The goal is to see if thes…

This early-stage study tests a new type of CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses the patient's own immune cells, modified to target and calm the overactive immune system. The goal is to reduce disease activ…

This early-stage study tests a new treatment using a patient's own immune cells, engineered to target a protein called CEA found on certain cancer cells. It is for adults with advanced lung, stomach, colon, rectal, esophageal, or pancreatic cancer who have not responded to standa…

This early-phase study tests a personalized cell therapy (CAR-T) for people with severe lupus that hasn't responded to standard treatments. The therapy uses the patient's own immune cells, modified to target and calm overactive B cells. The goal is to reduce disease activity and …

This early-stage study tests a new, fast-made CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses a person's own immune cells, modified to target and calm the overactive immune system causing lupus. The main goals are to…

This early-stage trial tests a new treatment called MC-1-50 for adults with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. The main goal is to check s…

This early study tests a new type of CAR T-cell therapy for adults with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not improved with standard treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The mai…